ALL-442 Patient-reported Outcomes in Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Genetics

Show all topics

DOI

10.1016/s2152-2650(24)01113-3